Beam Therapeutics

Beam Therapeutics
https://beamtx.com

Field:
Genetic Engineering

Focus:
Body

Type: Public Corporation
Founded: 2017
HQ: United States

Beam is pioneering the use of base editing — a potential new class of precision genetic medicines — with a vision of providing life-long cures to patients suffering from serious diseases.
[Learn +]
Leadership
David Liu
Founder (not involved anymore)
[LinkedIn]

Feng Zhang
Founder (not involved anymore)
[LinkedIn]
[Twitter]

Financial Performance


Funding


Raised Capital
Year
Type
Offered / Sold Amount
Filings
Reported by Press*
Round
2018
83.6 / 83.6M USD
U.S. SEC Form D
87M USD
Series A
2019
135.0 / 135.0M USD
U.S. SEC Form D
135M USD
Series B
2020
180M USD
Post-IPO Equity
Known Investors
Name
Type
HQ
Other Relevant Investments
Altitude Life Science Ventures
Venture Capital
United States
ARCH Venture Partners
Venture Capital
United States
Elysium Health
Aira
Locanabio
Prime Medicine
Cormorant Asset Management
Private Equity
United States
Eight Roads Ventures
Venture Capital
United Kingdom
F-Prime
Venture Capital
United States
Prime Medicine
GV
Corporate Venture
United States
CTRL-labs
Locanabio
Prime Medicine
Editas Medicine
Hunt BioVentures
Venture Capital
United States
Omega Funds
Venture Capital
United States
Editas Medicine
Osage University Partners
Venture Capital
United States
Cell Design Labs
Redmile Group
Private Equity
United States
*More data available at: [CB Insights] [CrunchBase] [PitchBook]
Related
News
Researchers have developed “prime editing,” a true search-and-replace function for DNA